1152131-73-1

Basic information

• Product Name: 5-{4-[3-chloro-4-(3-fluorobenzyloxy)phenylamino]quinazolin-6-yl}furan-2-carboxylic acid
• Synonyms: 5-{4-[3-chloro-4-(3-fluorobenzyloxy)phenylamino]quinazolin-6-yl}furan-2-carboxylic acid
• CAS NO: 1152131-73-1
• Molecular Weight: 489.89
• Mol File: 1152131-73-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 5-{4-[3-chloro-4-(3-fluorobenzyloxy)phenylamino]quinazolin-6-yl}furan-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-{4-[3-chloro-4-(3-fluorobenzyloxy)phenylamino]quinazolin-6-yl}furan-2-carboxylic acid(1152131-73-1)
• EPA Substance Registry System: 5-{4-[3-chloro-4-(3-fluorobenzyloxy)phenylamino]quinazolin-6-yl}furan-2-carboxylic acid(1152131-73-1)

Safety Data

• Hazardous Substances Data: 1152131-73-1(Hazardous Substances Data)

Upstream product

• 27329-70-0 5-formylfurane-2-boronic acid 
• 231278-20-9 N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine 
• 231278-84-5 5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-carbaldehyde 
• 202197-26-0 3-chloro-4-(3-fluorobenzyloxy)aniline 
• 5326-47-6 2-amino-5-iodobenzoic acid 
• 456-47-3 3-fluoro-benzenemethanol 
• 350-30-1 3-chloro-4-fluoronitrobenzene 
• 98556-31-1 4-chloro-6-iodoquinazoline 
• 16064-08-7 6-iodo-1H-quinazolin-4-one 
• 443882-99-3 3-chloro-4-(3-fluorobenzyloxy)nitrobenzene 
• 852228-11-6 5-boronofuran-2-carboxylic acid 

Downstream Products

• 1152131-87-7 5-{4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl}furan-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 
• 1152131-99-1 5-{4-[3-chloro-4-(3-fluorobenzyloxy)phenylamino]quinazolin-6-yl}furan-2-carboxylic acid hydroxyamide hydrochloride 
• 1152131-89-9 5-{4-[3-chloro-4-(3-fluorobenzyloxy)phenylamino]quinazolin-6-yl}furan-2-carboxylic acid (2-aminophenyl)amide 
• 1421356-24-2 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((4-hydroxybutyl)amino)methyl)-2-furyl)-4-quinazolinamine 
• 1421356-36-6 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((4-methoxybutyl)amino)methyl)-2-furyl)-4-quinazolinamine 
• 1421356-85-5 N-(3-chloro-4-((3-fluorobenzyl)oxyphenyl)-6-(5-((4-hydroxybutyl)amino)formyl)-2-furyl)-4-quinazolinamine 
• 1275595-86-2 N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfinylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine 

Relevant articles and documents

QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT

A class of quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof with novel structures is provided; meanwhile, a pharmaceutical composition comprising a pharmaceutically effective amount of said quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof, and pharmaceutically acceptable excipients or additives is also provided. By modifying and transforming the quinazoline and screening of the transformed compounds on the activity of tyrosine kinase inhibition, most of the compounds have been found to possess inhibitory activity against one or several of EGFR, VEGFR-2, c-erbB-2, c-erbB-4, c-met, tie-2, PDGFR, c-src, lck, Zap70 and fyn kinases. The present invention has the advantages of reasonable design, broad source of and easy access to the raw materials, simple and easy operation of the preparation methods, mild reaction conditions, high yield of the products and being beneficial for industrial-scale production.

Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer

To develop potent dual EGFR/HER-2 inhibitors with improved druggability, a series of new lapatinib analogs were designed and synthesized. Compared with lapatinib, L-2, L-4 and M-6 were more active against BT-474 or NCI-N87 cells. In vivo efficacy studies indicated that L-2 significantly suppressed tumor growth in NCI-N87 (94.8% inhibition) or SK-OV-3 xenograft (85.7% inhibition) without causing significant loss of body weight. And the inhibition rates of lapatinib in the two xenograft models were 89.7% and 78.8%, respectively. Moreover, further studies revealed that the potent in vivo activities of L-2 may be mainly attributed to its superior aqueous solubility and oral bioavailability. In addition, a high-yielding one-pot procedure was developed for the synthesis of lapatinib and its analogs.

NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES

The present invention relates to a bifunctional compound of formula I or its pharmaceutically acceptable salts or solvates A-L-B (I) wherein A is a histone deacetylase (HDAC) inhibitory moiety, L is a single bond or a linker group and B is a protein kinase inhibitory moiety. The bifunctional compound according to formula (I) is useful for the treatment of malignant and non-malignant neoplasia and diseases related to abnormal cell growth